Streetbeat News

PNT

POINT Biopharma Global Inc

pointbiopharma.com

CEO

Joe A. McCann

Employees

132

Industry

Pharmaceutical Preparation Manufacturing

a novel, research based biotechnology company focused on the development and commercialization of radiopharmaceutical products to meet unmet patient needs

Open

12.50

Mkt cap

1.3B

Volume

3.3M

High

12.51

P/E Ratio

11.36

52-wk high

14.35

Low

12.49

Div yield

N/A

52-wk low

6.57

Fusion Pharmaceuticals Inc (FUSN) is highlighted as a key player in the targeted radiopharmaceutical therapy (TRT) space by Oppenheimer, especially after recent acquisitions by Bristol Myers Squibb & Co (BMY) and Eli Lilly And Co (LLY). Fusion's partnership with AstraZeneca Plc (AZN) on advancing targeted radiotherapies and a profit-sharing agreement could position AstraZeneca for future acquisitions. Raymond James upgraded Fusion's stock from Outperform to Strong Buy with a price target of $15.

Portfolio Pulse from Vandana Singh

December 27, 2023 | 5:42 pm

Brookline Capital analyst Kemp Dolliver downgraded POINT Biopharma Global (PNT) from Buy to Hold and reduced the price target from $27 to $12.5.

Portfolio Pulse from Benzinga Newsdesk

December 21, 2023 | 10:47 am

Lantheus Holdings Inc (LNTH) and POINT Biopharma Global Inc (PNT) reported positive Phase 3 SPLASH trial results for 177Lu-PNT2002 in treating metastatic castration-resistant prostate cancer. The trial met its primary endpoint, showing a significant reduction in the risk of radiographic progression or death. Despite favorable safety profiles and efficacy, LNTH and PNT stocks are trading lower, with LNTH down 23.05% and PNT down 11.13%.

Portfolio Pulse from Vandana Singh

December 18, 2023 | 4:47 pm

POINT Biopharma's stock is trading lower following the announcement of topline results from the phase 3 SPLASH study for metastatic castration-resistant prostate cancer, conducted in collaboration with Lantheus.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 4:34 pm

Lantheus Holdings, Inc. (LNTH) and POINT Biopharma Global Inc. (PNT) announced positive topline results from the Phase 3 SPLASH study for 177Lu-PNT2002, a treatment for metastatic castration-resistant prostate cancer. The study met its endpoints, showing efficacy and safety after progression on an ARPI.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 12:31 pm

Eli Lilly has extended the expiration date of its tender offer for POINT Biopharma from the previously scheduled date in December to December 15, 2023.

Portfolio Pulse from Benzinga Newsdesk

December 04, 2023 | 11:48 am

Five health care stocks are considered overbought based on their RSI values, which may signal a potential short-term decline. OraSure Technologies (OSUR) reported positive quarterly results but saw a slight share price drop. POINT Biopharma (PNT) reported a net loss and is being acquired by Lilly, with a minor share price decrease. Natera (NTRA) partnered with Merck for oncology research, experiencing a small share price fall. Doximity (DOCS) exceeded financial expectations, yet shares closed lower. Hims & Hers Health (HIMS) reported strong sales and announced a share repurchase program, with shares also closing down.

Portfolio Pulse from Lisa Levin

November 17, 2023 | 1:33 pm

Eli Lilly and Company has extended its tender offer to acquire POINT Biopharma until December 1, 2023. The purchase price offered is $12.50 per share in cash.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 11:48 am

Eli Lilly and Company (LLY) has received consent from the Nuclear Regulatory Commission (NRC) for its proposed acquisition of POINT Biopharma (PNT). This regulatory consent is a significant step towards completing the acquisition process.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 9:35 pm

POINT Biopharma Global (NASDAQ:PNT) reported Q3 earnings, beating estimates with an EPS of $-0.23 against the expected $-0.3. Revenue increased by $2.79 million from the previous year. Despite beating EPS last quarter, the stock dropped by 3.82% the following day.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 12:35 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.